ACS Dobfar SPA

U.S. drug recalls increased in 2013 to the third-highest level ever, driven by microbial and particulate contamination at pharmaceutical compounding and manufacturing facilities. In all, there were 1,

U.S. drug recalls increased in 2013 to the third-highest level ever, driven by microbial and particulate contamination at pharmaceutical compounding and manufacturing facilities. In all, there were 1,

Two years ago it looked as if all was lost at Pharming: escalating costs for its Pompe's disease program and indebtedness to its JV partner Genzyme forced it into legal moratorium in August 2001. Toda

With an FDA willing and able to change the rules midstream, attempting to lower development risk can be a chimera. The ultimate risk reduction strategy is creating a diverse pipeline. By Jeffrey Dvori